184 related articles for article (PubMed ID: 22089153)
1. [Myocardial metastasis from renal cell carcinoma treated with sorafenib].
Tokuyama Y; Iwamura M; Fujita T; Sugita A; Maeyama R; Bessho H; Ishikawa W; Tabata K; Yoshida K; Baba S
Hinyokika Kiyo; 2011 Oct; 57(10):555-8. PubMed ID: 22089153
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
[TBL] [Abstract][Full Text] [Related]
3. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.
Valcamonico F; Ferrari V; Amoroso V; Rangoni G; Simoncini E; Marpicati P; Vassalli L; Grisanti S; Marini G
J Neurooncol; 2009 Jan; 91(1):47-50. PubMed ID: 18712279
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib rechalenge in metastatic renal cell carcinoma.
Porta C; Paglino C; Imarisio I
BJU Int; 2012 Sep; 110(6 Pt B):E235. PubMed ID: 22332769
[No Abstract] [Full Text] [Related]
5. Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.
Lekili M; Muezzinoglu T; Nese N; Temeltas G
J Chin Med Assoc; 2010 May; 73(5):262-4. PubMed ID: 20685594
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
Mizutani Y
Int J Urol; 2009 May; 16(5):444-8. PubMed ID: 19298634
[TBL] [Abstract][Full Text] [Related]
7. Editorial comment to Treatment outcomes of sorafenib for first line or cytokine-refractory advanced renal cell carcinoma in Japanese patients.
Tomita Y
Int J Urol; 2010 Sep; 17(9):815-6. PubMed ID: 20727052
[No Abstract] [Full Text] [Related]
8. Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report.
Castagneto B; Stevani I; Giorcelli L; Montefiore F; Bigatti GL; Pisacco P; Cosimi MF
Med Oncol; 2011 Dec; 28(4):1384-8. PubMed ID: 20552299
[TBL] [Abstract][Full Text] [Related]
9. Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
Raspollini MR
Curr Oncol Rep; 2007 Sep; 9(5):331. PubMed ID: 17706159
[No Abstract] [Full Text] [Related]
10. Sorafenib [corrected] in kidney cancer.
Escudier B
Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
[No Abstract] [Full Text] [Related]
11. [Tegafur-uracil markedly reduced pulmonary metastasis from renal cell carcinoma refractory to sorafenib, interferon and interleukin 2].
Morimoto H; Tsuzaka Y; Kaneko T; Matsushima H; Homma Y
Gan To Kagaku Ryoho; 2010 Oct; 37(10):2007-10. PubMed ID: 20948275
[TBL] [Abstract][Full Text] [Related]
12. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
13. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
Desar IM; Mulder SF; Stillebroer AB; van Spronsen DJ; van der Graaf WT; Mulders PF; van Herpen CM
Acta Oncol; 2009; 48(6):927-31. PubMed ID: 19452305
[No Abstract] [Full Text] [Related]
14. Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.
Hou MM; Hsieh JJ; Chang NJ; Huang HY; Wang HM; Chuang CK; Hsu T; Chang JW
Clin Drug Investig; 2010; 30(11):799-804. PubMed ID: 20635828
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.
Zhang H; Dong B; Lu JJ; Yao X; Zhang S; Dai B; Shen Y; Zhu Y; Ye D; Huang Y
BMC Cancer; 2009 Jul; 9():249. PubMed ID: 19622166
[TBL] [Abstract][Full Text] [Related]
17. The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
Imarisio I; Paglino C; Ganini C; Magnani L; Caccialanza R; Porta C
Future Oncol; 2012 Aug; 8(8):1051-7. PubMed ID: 22894676
[TBL] [Abstract][Full Text] [Related]
18. Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
Massard C; Zonierek J; Gross-Goupil M; Fizazi K; Szczylik C; Escudier B
Ann Oncol; 2010 May; 21(5):1027-31. PubMed ID: 19850637
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib rechallenge in patients with metastatic renal cell carcinoma.
Nozawa M; Yamamoto Y; Minami T; Shimizu N; Hatanaka Y; Tsuji H; Uemura H
BJU Int; 2012 Sep; 110(6 Pt B):E228-34. PubMed ID: 22332735
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]